(Q38013964)

27 August 2017

title

Cancer immunotherapy: a paradigm shift for prostate cancer treatment (English)

1 reference

27 August 2017

1 reference

1 reference

1 reference

Dev Karan

1

1 reference

27 August 2017

Jeffrey M Holzbeierlein

series ordinal

2

1 reference

27 August 2017

Peter Van Veldhuizen

series ordinal

3

1 reference

27 August 2017

J Brantley Thrasher

series ordinal

4

1 reference

27 August 2017

language of work or name

English

0 references

publication date

29 May 2012

1 reference

27 August 2017

published in

Nature Reviews Urology

1 reference

27 August 2017

volume

9

1 reference

27 August 2017

issue

7

1 reference

27 August 2017

page(s)

376-385

1 reference

https://scigraph.springernature.com/pub.10.1038/nrurol.2012.106

27 August 2017

exact match

0 references

cites work

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Prostate cancer: genes, environment, immunity and the use of immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Expanding treatment options for metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

The economic burden of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Lifetime economic burden of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Cancer: a biological approach. III. Viruses associated with neoplastic conditions. IV. Practical applications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

21 January 2018

Inflammation and cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

The role of inflammation in the pathogenesis of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

The PCa Tumor Microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Escape from immunotherapy: possible mechanisms that influence tumor regression/progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Tumor escape mechanisms in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Mechanisms of tumor escape: role of tumor microenvironment in inducing apoptosis of cytolytic effector cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Immune signatures of murine and human cancers reveal unique mechanisms of tumor escape and new targets for cancer immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Cancer immunoediting: from immunosurveillance to tumor escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Introduction: current concepts in immunity to human cancer and therapeutic antitumor vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Paradoxical enhancement of CD8 T cell-dependent anti-tumor protection despite reduced CD8 T cell responses with addition of a TLR9 agonist to a tumor vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

RNA as a tumor vaccine: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Tumor Vaccine Design: Concepts, Mechanisms, and Efficacy Testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Cancer vaccines as a therapeutic modality: The long trek

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Cancer immunotherapy: moving beyond current vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Novel cancer immunotherapy agents with survival benefit: recent successes and next steps

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Prostate cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Harnessing human dendritic cell subsets for medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Immunotherapy with dendritic cells for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Cancer immunotherapy with mRNA-transfected dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Listeria and Salmonella bacterial vectors of tumor-associated antigens for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Listeria monocytogenes as a vector for tumor-associated antigens for cancer immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Multiple effector mechanisms induced by recombinant Listeria monocytogenes anticancer immunotherapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Cytosolic entry controls CD8+-T-cell potency during bacterial infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Development of a Listeria monocytogenes-based vaccine against hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Listeria monocytogenes as a vector for anti-cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Cancer immunotherapy using recombinant Listeria monocytogenes: transition from bench to clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

A novel human Her-2/neu chimeric molecule expressed by Listeria monocytogenes can elicit potent HLA-A2 restricted CD8-positive T cell responses and impact the growth and spread of Her-2/neu-positive breast tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Development of a Listeria monocytogenes based vaccine against prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Construction and characterization of an attenuated Listeria monocytogenes strain for clinical use in cancer immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Adenoviruses as vectors for delivering vaccines to mucosal surfaces

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Conditionally replicating viruses in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Development and application of adenoviral vectors for gene therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (ALVAC) cytokine gene delivery induces destruction of established prostate tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Oral tolerization to adenoviral proteins permits repeated adenovirus-mediated gene therapy in rats with pre-existing immunity to adenoviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

A simple method for the rapid generation of recombinant adenovirus vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Good manufacturing practice production of adenoviral vectors for clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Adenoviruses as vaccine vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Induction of CD8 T cells by vaccination with recombinant adenovirus expressing human papillomavirus type 16 E5 gene reduces tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

10-year safety follow-up in patients with local VEGF gene transfer to ischemic lower limb

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Biodistribution and toxicological safety of adenovirus type 5 and type 35 vectored vaccines against human immunodeficiency virus-1 (HIV-1), Ebola, or Marburg are similar despite differing adenovirus serotype vector, manufacturer's construct, or gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Cutting edge: restoration of the ability to generate CTL in mice immune to adenovirus by delivery of virus in a collagen-based matrix

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Phase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Presentation of tumour antigens by dendritic cells and challenges faced.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Migration of dendritic cell based cancer vaccines: in vivo veritas?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

CD40-targeted recombinant adenovirus significantly enhances the efficacy of antitumor vaccines based on dendritic cells and B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Potent antitumor immunity generated by a CD40-targeted adenoviral vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Efficient transfer of PSA and PSMA cDNAs into DCs generates antibody and T cell antitumor responses in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Immunotherapeutics in development for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Prostate stem cell antigen: a prospective therapeutic and diagnostic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Cancer immunotherapy comes of age

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Cancer immunotherapy comes of age

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Immunologic biomarkers as correlates of clinical response to cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Laparoscopic partial nephrectomy and prostatectomy: weighing the costs and the benefits

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Immunotherapy for prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Features of the dendritic cell lineage

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

CD54 is a surrogate marker of antigen presenting cell activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Decreased cytotoxic T cell activity generated by co-administration of PSA vaccine and CpG ODN is associated with increased tumor protection in a mouse model of prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Evaluation of the transfer and expression in mice of an enzyme-encoding gene using a human adenovirus vector

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Immunologic monitoring of cellular immune responses in cancer vaccine therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.106

Immunotherapy in the treatment of advanced prostate cancer.

31 March 2020

1 reference

12 December 2020

Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia

1 reference

12 December 2020

Human colorectal cancer (CRC) antigen CO17-1A/GA733 encoded by adenovirus inhibits growth of established CRC cells in mice.

1 reference

12 December 2020

The concept of immunological surveillance

1 reference

12 December 2020

The role of immunotherapy in prostate cancer: an overview of current approaches in development.

1 reference

12 December 2020

Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer

1 reference

12 December 2020

Vaccines for immunotherapy of breast cancer and prostate cancer: new developments and comparative aspects.

1 reference

12 December 2020

Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRUROL.2012.106

1 reference

Dimensions Publication ID

27 August 2017

1035759038

0 references

1 reference